Oxford Asset Management’s Matinas BioPharma MTNB Stock Holding History

Oxford Asset Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-148	Closed	-$251K	–	882
2019 Q4	$251K	Buy	148 +127	+605%	+$110K	0.01%	1490
2019 Q3	$10K	Buy	+21	New	+$11.4K	﹤0.01%	1669
2018 Q3	–	Sell	-44	Closed	-$14K	–	1847
2018 Q2	$14K	Buy	+44	New	+$19.1K	﹤0.01%	1666

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Oxford Asset Management's MTNB Position: Q1 2020 in Review

Oxford Asset Management sold out of Matinas BioPharma (MTNB) in Q1 2020, closing a stake of 148 shares — an estimated $251K sold.

Oxford Asset Management first reported a position in MTNB in Q2 2018 and held it in 3 quarters. The position peaked at $251K in Q4 2019. 64 funds tracked by Wall St. Rank hold MTNB as of Q1 2020.

Oxford Asset Management reported no remaining Matinas BioPharma position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 148 Matinas BioPharma shares in Q1 2020, an estimated $251K.
Oxford Asset Management first reported a position in Matinas BioPharma in Q2 2018 and held it in 3 quarters.
Oxford Asset Management's Matinas BioPharma position peaked at $251K in Q4 2019.
64 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.